Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 201–300 of 1,000
Yu, L., Huang, L., Lin, D., Lai, X., Wu, L., Liao, X., Liu, J., Zeng, Y., Liang, L., Zhang, G., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03839-5 · Cited by 102
Vassal, G., Rousseau, R., Blanc, P., Moreno, L., Bode, G., Schwoch, S., Schrappe, M., Skolnik, J., Bergman, L., Bradley-Garelik, M. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.029 · Cited by 93
Morgenstern, D. A., London, W. B., Stephens, D., Volchenboum, S. L., Simon, T., Nakagawara, A., Shimada, H., Schleiermacher, G., Matthay, K. K., Cohn, S. L., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.005 · Cited by 102
“Whether the addition of further treatment modalities for high-risk neuroblastoma, such as immunotherapy [22], may also impact on the significance of particular risk factors remains to be resolved.”
Self-citationSeitz, C. M., Schroeder, S. M., Knopf, P., Krahl, A.-C., Hau, J., Schleicher, S., Martella, M., Quintanilla‐Martínez, L., Kneilling, M., Pichler, B. J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1683345 · Cited by 99
“18, also known as dinutuximab beta.(22,23) In the present study, we used a GD2directed immunotherapy by GD2CAR-T to target BCSCs.”
MethodVillablanca, J. G., London, W. B., Naranjo, A. H., McGrady, P., Ames, M. M., Reid, J. M., McGovern, R. M., Buhrow, S. A., Jackson, H. A., Stranzinger, E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0995 · Cited by 100
“18 and cytokines to 13-cisRA maintenance further improves outcome (4).”
BackgroundSelf-citationRyan, J., Tivnan, A., Fay, J., Bryan, K., Meehan, M., Creevey, L., Lynch, J., Bray, I. M., O'Meara, A., Tracey, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.425 · Cited by 94
Immune-based therapies for childhood cancer
Mackall, C. L., Merchant, M. S., & Fry, T. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.177 · Cited by 98
Modak, S., Le Luduec, J.-B., Cheung, I. Y., Goldman, D. A., Ostrovnaya, I., Doubrovina, E., Basu, E., Kushner, B. H., Kramer, K., Roberts, S. S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461305 · Cited by 91
“tumor for which monoclonal antibody (MoAb)-based immunotherapy has been proven to be effective.(4) The murine anti-GD2 MoAb 3F8 (m3F8) induces complete remission (CR) in chemoresistant osteomedullary NB,(5) and improves survival in stage 4 NB patients in first(6) and subsequent remissions.”
BackgroundØra, I., & Eggert, A. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.07.002 · Cited by 107
“indicated a 2-year EFS of 66% compared to 46% in favor of the treatment [114, 118-120].”
ResultRetargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Xu, H., Cheng, M., Guo, H., Chen, Y., Huse, M., & Cheung, N.-K. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0230-t · Cited by 92
“18, when combinedwithGM-CSF and IL2, in preventing neuroblastoma relapse among patients in first complete remission (6).”
BackgroundLadenstein, R. L., Lambert, B., Pötschger, U., Castellani, M. R., Lewington, V. J., Bar‐Sever, Z., Oudoux, A., Śliwińska, A., Táborská, K., Biassoni, L., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3829-7 · Cited by 93
“Immunotherapy with anti-GD2 monoclonal antibody was only given to a minority of patients (Table 1) [16, 17].”
Self-citationCheung, N. V., Cheung, I. Y., Kramer, K., Modak, S. I., Kuk, D., Pandit-Taskar, N. D., Chamberlain, E., Ostrovnaya, I., & Kushner, B. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.28851 · Cited by 92
Green, D. M., Kun, L. E., Matthay, K. K., Meadows, A. T., Meyer, W. H., Meyers, P. A., Spunt, S. L., Robison, L. L., & Hudson, M. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24487 · Cited by 96
“01), will be the benchmark against which new therapies will be evaluated during the coming decade [60].”
BackgroundSelf-citationPiskareva, O., Harvey, H. M., Nolan, J., Conlon, R., Alcock, L., Buckley, P. G., Dowling, P., Henry, M. A., O’Sullivan, F., Bray, I. M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.004 · Cited by 101
“18, both of which have led to improved event free survival [2].”
BackgroundImmune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
Vanichapol, T., Chutipongtanate, S., Anurathapan, U., & Hongeng, S. (2018) · BioMed Research International · doi:10.1155/2018/1812535 · Cited by 99
Emerging trends in immunotherapy for pediatric sarcomas
Dyson, K. A., Stover, B. D., Grippin, A., Mendez-Gomez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 88
“Additionally, co-delivery of immune activating agonists, such as interleukin-2 (IL-2), in pediatric OS may serve as a necessary adjuvant for targeting overexpressed antigens [44, 51, 72, 73].”
BackgroundRössig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., Reinhardt, D., Burkhardt, B., Woessmann, W., Zimmermann, M., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24598 · Cited by 91
Pinto, N. R., Naranjo, A. H., Hibbitts, E., Kreissman, S. G., Granger, M. P., Irwin, M. S., Bagatell, R., London, W. B., Greengard, E. G., Park, J. R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.003 · Cited by 91
“The addition of myeloablative chemotherapy followed by autologous stem cell transplant rescue (ASCT) after induction therapy, improved surgical and radiotherapy techniques, and the use of both a differentiating agent (cis-retinoic acid) and a chimeric anti-GD2 antibody after transplantation have all led to incremental…”
BackgroundSelf-citationAdvances in paediatric cancer treatment.
Saletta, F., Seng, M. S.-F., & Lau, L. M. S. (2014) · PubMed Central · doi:10.3978/j.issn.2224-4336.2014.02.01 · Cited by 114
More than the genes, the tumor microenvironment in neuroblastoma
Borriello, L., Seeger, R. C., Asgharzadeh, S., & DeClerck, Y. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.017 · Cited by 103
Self-citationJubierre, L., Soriano, A., Planells‐Ferrer, L., París-Coderch, L., Tenbaum, S. P., Romero, O. A., Moubarak, R. S., Almazán-Moga, A., Molist, C., Roma, J. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.50 · Cited by 94
Knight, S. W. E., Knight, T. E., Santiago, T., Murphy, A. J., & Abdelhafeez, A. H. (2022) · Children · doi:10.3390/children9010038 · Cited by 92
“However, it is at least as common, if not more so, for mechanistically promising therapies to fail upon clinical translation [73,74].”
BackgroundOutcome for Children with Metastatic Solid Tumors over the Last Four Decades
Perkins, S. M., Shinohara, E. T., DeWees, T., & Frangoul, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100396 · Cited by 90
“In the past 10 years, survival was further improved with using immune therapy with Anti-GD2 therapy following ASCT [24].”
BackgroundTranslational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
Bassiri, H., Benavides, A. D., Haber, M., Gilmour, S. K., Norris, M. D., & Hogarty, M. D. (2015) · PubMed · doi:10.3978/j.issn.2224-4336.2015.04.06 · Cited by 96
“This is an important consideration given that an immunotherapy regimen consisting of anti-GD2 targeted antibody with GM-CSF and IL-2 has been shown to improve survival in neuroblastoma (11), and begs the question of whether DFMO exposures that target the (altering the tumor microenvironment to support anti-tumor immun…”
BackgroundOzkaynak, M. F., Gilman, A. L., London, W. B., Naranjo, A. H., Diccianni, M. B., Tenney, S. C., Smith, M. A., Messer, K. S., Seeger, R. C., Reynolds, C. P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01355 · Cited by 87
“Overall, this study confirmed the toxicity data and efficacy previously obtained in the ANBL0032 trial (1).”
BackgroundMethodResultInfluentialSelf-citationRole of immunotherapy in Ewing sarcoma
Morales, E., Olson, M., Cardenas, F. I., Dahiya, S., Luetkens, T., & Atanackovic, D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000653 · Cited by 98
Too many targets, not enough patients: rethinking neuroblastoma clinical trials
Fletcher, J. I., Ziegler, D. S., Trahair, T. N., Marshall, G. M., Haber, M., & Norris, M. D. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0003-x · Cited by 90
Opportunities and Challenges in Drug Development for Pediatric Cancers
Laetsch, T. W., DuBois, S. G., Bender, J. G., Macy, M. E., & Moreno, L. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0779 · Cited by 91
“For example, the anti-GD2 chimeric antibody dinutuximab was shown to improve two year event-free survival by 20% in patients with newly diagnosed high-risk neuroblastoma when given during the post-consolidation phase of therapy.(12) The bispecific T-cell engager (BiTE) antibody targeting-CD19 and CD3 blinatumomab has…”
BackgroundMorgenstern, D. A., Baruchel, S., & Irwin, M. S. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318299d637 · Cited by 96
GD2-Targeted Immunotherapy and Radioimmunotherapy
Dobrenkov, K., & Cheung, N. V. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.003 · Cited by 85
“18 with GMCSF, IL-2, and isotretinoin for NB (113) Randomized phase III/ NCT00026312/ [18] 25, daily for 4 days, 5 cycles Pain, capillary leak syndrome, hypersensitivity reactions Superior OS in immunotherapy group as compared to standard therapy Ch14.”
ResultPreclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M., Chen, L., Martinez, D., Li, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1131 · Cited by 82
“This finding suggests that ultimately this combination may be most useful in the maintenance stage of treatmentwhenpatientswith high-risk diseasewhohave achieved a complete response to chemotherapy, but arepresumed toharbor chemotherapy-resistantminimal residual disease, are treatedwith the retinoid isotretinoin in co…”
Self-citationCurrent management of neuroblastoma and future direction
Pastor, E. R., & Mousa, S. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.013 · Cited by 87
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 98
Immunology and immunotherapy of neuroblastoma
Seeger, R. C. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.012 · Cited by 95
“Although EFS was improved by adding immunotherapy to cisRA, approximately 40% of patients still relapsed during or after this therapy (7).”
BackgroundSelf-citationLadenstein, R. L., Weixler, S., Baykan, B., Bleeke, M., Kunert, R., Katinger, D., Pribill, I., Glander, P., Bauer, S., Pistoia, V., et al. (2013) · mAbs · doi:10.4161/mabs.25215 · Cited by 86
“18 is a human/mouse chimeric antibody consisting of variable regions derived from the murine anti-GD 2 antibody 14G2a and constant regions from a human IgG1 molecule.(6,12-16) The ch14.”
BackgroundCole, K. A., & Maris, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1409 · Cited by 87
Self-citationForlenza, C. J., Boudreau, J. E., Zheng, J., Luduec, J.-B. L., Chamberlain, E., Heller, G., Cheung, N. V., & Hsu, K. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9558 · Cited by 88
Yanik, G. A., Parisi, M. T., Naranjo, A. H., Nadel, H. R., Gelfand, M. J., Park, J. R., Ladenstein, R. L., Pöetschger, U., Boubaker, A., Valteau‐Couanet, D., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195883 · Cited by 85
“]) after transplantation in combination with granulocyte–macrophage colony-stimulating factor and intravenous interleukin-2 has led to improvements in EFS (4).”
BackgroundSelf-citationTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 81
Keyel, M. E., & Reynolds, C. P. (2018) · Biologics · doi:10.2147/btt.s114530 · Cited by 94
“conclusively demonstrated that adding dinutuximab + GMCSF + IL-2 to maintenance therapy with 13-cis-RA significantly improved outcome.(5) Results with other anti-GD2 antibodies, although not tested in a randomized fashion, are similar.”
InfluentialSelf-citationInterleukin-2–based therapies in cancer
Raeber, M. E., Şahin, D., & Boyman, O. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5409 · Cited by 88
“(3, 4, 57) Indicated for melanoma (FDA-approved 1998), renal cell carcinoma (FDA-approved 1992), and combination of anti-ganglioside GD2 antibody, GM-CSF, isotretinoin and aldesleukin for neuroblastoma (FDAapproved 2015).”
BackgroundSoldati, R., Berger, E., Zenclussen, A. C., Jorch, G., Lode, H. N., Salatino, M., Rabinovich, G. A., & Fest, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.26498 · Cited by 79
“Treatment with IL-2, GM-CSF, CD40 agonists or CTLA-4 blockade, in combination with other traditional approaches, has successfully improved immune effector functions in high-risk NB patient.(5,6) However, the success of these adjuvant immunotherapeutic approaches is hindered by a number of strategies used by tumors or…”
BackgroundTas, M. L., Reedijk, A., Karim‐Kos, H. E., Kremer, L. C. M., van de Ven, C. P., Dierselhuis, M. P., van Eijkelenburg, N. K. A., van Grotel, M., Kraal, K. C. J. M., Peek, A. M. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.025 · Cited by 82
“This cohort seems to confirm earlier studies demonstrating a benefit for maintenance therapy with immunotherapy [12,38].”
ResultGaraventa, A., Pöetschger, U., Valteau‐Couanet, D., Luksch, R., Castel, V., Elliott, M., Ash, S., Chan, G., Laureys, G., Popovic, M. B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03144 · Cited by 84
“(%) Evaluable 596 (95) 294 (94) 302 (95) Cervical 35 (6) 15 (5) 20 (7) Thoracic 100 (17) 48 (16) 52 (17) Abdominal adrenal 403 (68) 208 (71) 195 (65) Abdominal other 228 (38) 111 (38) 117 (39) Pelvic 45 (8) 20 (7) 25 (8)”
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
Reppel, L., Tsahouridis, O., Akulian, J., Davis, I. J., Lee, H., Fucà, G., Weiss, J., Dotti, G., Pecot, C. V., & Savoldo, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003897 · Cited by 89
Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors
Cavdarli, S., Groux‐Degroote, S., & Delannoy, P. (2019) · Biomolecules · doi:10.3390/biom9080311 · Cited by 87
“In the same manner, the combination of 14G2a with either PI3K/Akt/mTOR inhibitor or aurora kinase A enhanced the cytotoxicity effect by decreasing MYCN amplification and activation of pleckstrin homology like-domain family member 1 (PHLDA1) and p53 in LAN-1, CHP-132 and IMR-32 NBL cell lines [90,94].”
BackgroundAnti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets
Yankelevich, M., Kondadasula, S. V., Thakur, A. B., Buck, S. A., Cheung, N. V., & Lum, L. G. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24237 · Cited by 80
“Although survival rates increased in high-risk patients treated with naked anti-GD2 mAb in combination with cytokines, only 63% of Stage 4 patients remained free of disease at 2 years [6].”
BackgroundInfluentialSingh, N., Liu, X., Hulitt, J., Jiang, S., June, C. H., Grupp, S. A., Barrett, D. M., & Zhao, Y. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0051 · Cited by 77
“On the basis of these findings, as well as our own experience with RNA CAR T cells in ALL, we evaluated a CAR targeting GD2, a diasialoganglioside expressed on the surface of most neuroblastomas (1) that has already been shown to be an effective target for neuroblastoma immunotherapy (23).”
Self-citationEarly phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
Moreno, L., Pearson, A. D. J., Paolettí, X., Jiménez, I., Geoerger, B., Kearns, P. R., Zwaan, C. M., Doz, F., Baruchel, A., Vormoor, J. H., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.59 · Cited by 81
Oesterheld, J. E., Ferguson, W. S., Kraveka, J. M., Bergendahl, G., Clinch, T., Lorenzi, E., Berry, D. A., Wada, R. K., Isakoff, M. S., Eslin, D. E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02875 · Cited by 78
“25-28 PSM works best in a large data set, and our external control population 3,4 without missing covariates was suf fi ciently large to allow a 3:1 match.”
BackgroundImmunosuppressive Microenvironment in Neuroblastoma
Pistoia, V., Morandi, F., Bianchi, G., Pezzolo, A., Prigione, I., & Raffaghello, L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00167 · Cited by 82
“Immunotherapy proved to be associated with significantly improved outcome with regard to event-free survival and overall survival (Yu et al., 2010).”
BackgroundMethodPrimer on tumor immunology and cancer immunotherapy
Harris, T. J., & Drake, C. G. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-12 · Cited by 86
Santilli, G., Piotrowska, I., Cantilena, S., Chayka, O., D’Alicarnasso, M., Morgenstern, D. A., Himoudi, N., Pearson, K., Anderson, J., Thrasher, A. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2528 · Cited by 78
“Thus, we hypothesize that the increased numbers of myeloid cells in the blood of patients with neuroblastoma could interfere with the antitumor immune response and explain the failure of a significant proportion of patients to respond to immunotherapy (27).”
BackgroundSahu, D., Hsu, C., Lin, C.-C., Yang, T.-W., Hsu, W., Ho, S., Juan, H., & Huang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11158 · Cited by 83
“Therapeutic strategies such as targeting neuroblastoma cell surface disialoganglioside GD2 antigen with monoclonal antibodies has also shown a substantial improvement in the patient outcome [15].”
BackgroundAdvances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
Voeller, J., & Sondel, P. M. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001369 · Cited by 77
Self-citationIn vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma
Pressey, J. G., Adams, J. M., Harkins, L. E., Kelly, D. R., You, Z., & Lamb, L. S. (2016) · Medicine · doi:10.1097/md.0000000000004909 · Cited by 77
“In the setting of minimal residual disease following consolidative SCT and radiotherapy, maintenance immunotherapy with dinutuximab, a US Food and Drug Administration approved chimeric 14.18 anti-disialoganglioside GD2 antibody, given concurrently with IL-2 and granulocyte macrophage-colony stimulating factor has also…”
BackgroundInfluentialTerzić, T., Cordeau, M., Herblot, S., Teira, P., Cournoyer, S., Beaunoyer, M., Peuchmaur, M. M., Duval, M., & Sartelet, H. (2017) · Pediatric and Developmental Pathology · doi:10.1177/1093526617723972 · Cited by 77
“Recent introduction of immunotherapy to treat minimal residual disease after myeloablative therapy and bone marrow rescue has shown promising results and significantly improved the survival of high-risk NT patients.(10) The immunotherapeutic regimen consists of the combination of a chimeric human-murine monoclonal ant…”
BackgroundInfluentialMolecular mechanisms and therapeutic targets in neuroblastoma
Johnsen, J. I., Dyberg, C. H., Fransson, S. M., & Wickström, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.023 · Cited by 88
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
Chan, G., & Chan, C. M. (2022) · Biomolecules · doi:10.3390/biom12030358 · Cited by 83
“in high-risk neuroblastoma significan ly [5,17,18].”
BackgroundInfluentialBiology of GD2 ganglioside: implications for cancer immunotherapy
Machy, P., Mortier, E., & Birklé, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1249929 · Cited by 83
“As mentioned earlier, a common acute side effect upon antiGD2 mAb infusions is severe pain that limits the administrable dose to patients (Ozkaynak et al., 2000; Yu et al., 2010; Kushner et al., 2011; Tong et al., 2015; Ladenstein et al., 2018).”
BackgroundImmunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies
Casey, D. L., & Cheung, N. V. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0692 · Cited by 83
“Cancer Immunol Res; 8(2) February 2020 CANCER IMMUNOLOGY RESEARCH 162”
BackgroundInfluentialDavis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Nallasamy, P., Chava, S. P., Verma, S. S., Mishra, S., Gorantla, S., Coulter, D. W., Byrareddy, S. N., Batra, S. K., Gupta, S. C., & Challagundla, K. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.009 · Cited by 84
Xu, Y., Sun, J., Sheard, M. A., Tran, H. C., Wan, Z., Liu, W. Y., Asgharzadeh, S., Sposto, R., Wu, H. W., & Seeger, R. C. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1466-y · Cited by 75
Self-citationA phase II study of radioimmunotherapy with intraventricular 131I‐3F8 for medulloblastoma
Kramer, K., Pandit-Taskar, N. D., Humm, J. L., ZANZONICO, P. B., Haque, S. S., Dunkel, I. J., Wolden, S. L., Donzelli, M. A., Goldman, D. A., Lewis, J. S., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26754 · Cited by 75
“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
Liu, K. X., & Joshi, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01947 · Cited by 84
Anti-GD2 strategy in the treatment of neuroblastoma
Yang, R. K., & Sondel, P. M. (2010) · Drugs of the Future · doi:10.1358/dof.2010.035.08.1513490 · Cited by 84
Self-citationDuBois, S. G., Chesler, L., Groshen, S. G., Hawkins, R. A., Goodarzian, F., Shimada, H., Yanik, G. A., Tagen, M., Stewart, C., Mossé, Y. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3201 · Cited by 74
“Despite recent improvements in outcomes, patients with metastatic neuroblastoma continue to be at high risk for treatment failure (2, 3).”
BackgroundSelf-citationLi, Z., Yan, S., Attayan, N., Ramalingam, S., & Thiele, C. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3321 · Cited by 80
Anti-GD2 MABS and Next-Generation mAb-Based Agents for Cancer Therapy
Horta, Z. P., Goldberg, J. L., & Sondel, P. M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0021 · Cited by 76
Self-citationMueller, I., Ehlert, K., Endres, S., Pill, L., Siebert, N., Kietz, S., Brock, P. R., Garaventa, A., Valteau‐Couanet, D., Janzek, E., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1402997 · Cited by 80
“In order to improve the toxicity profile, we investigated a new delivery method by long-term continuous infusion of 100 mg/m(2) per cycle over 10 days, which was described to be a clinically active and effective cumulative dose in the treatment of NB.(3,10)”
BackgroundMethodResultInfluentialMoreno, L., Barone, G., DuBois, S. G., Molenaar, J. J., Fischer, M., Schulte, J. H., Eggert, A., Schleiermacher, G., Speleman, F., Chesler, L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.010 · Cited by 79
“Aucune autre utilisation n ́est cytokines (granulocyteemacrophage colony-stimulating factor and interleukin 2), in addition to isotretinoin [58].”
BackgroundSelf-citationAndersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., Jensen, M. C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6131-1 · Cited by 79
Cytotoxic Immunity in Peripheral Nerve Injury and Pain
Davies, A. J., Rinaldi, S., Costigan, M., & Oh, S. B. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00142 · Cited by 77
“The combination of anti-GD2 mAbs with IL-2 improves outcomes in high-risk neuroblastoma patients suggesting that cellular effectors, in particular NK cells, are key to this response (Yu et al., 2010).”
BackgroundCancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy
Groux‐Degroote, S., & Delannoy, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116145 · Cited by 75
“A randomized clinical trial demonstrated a significant improvement of patient outcomes (improved event-free survival and overall survival) when Dinutuximab was used in combination with a granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-2, and 13-cis retinoic acid in the treatment of pediatric pat…”
Targeting macrophages: a novel treatment strategy in solid tumors
Liu, M., Liu, L., Song, Y., Li, W., & Xu, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03813-w · Cited by 77
Lasky, J. L., Panosyan, E. H., Plant, A., Davidson, T. B., Yong, W. H., Prins, R. M., Liau, L. M., & Moore, T. B. (2013) · PubMed · Cited by 76
Yang, R. K., Kalogriopoulos, N. A., Rakhmilevich, A. L., Ranheim, E. A., Seo, S., Kim, K., Alderson, K. L., Gan, J., Reisfeld, R. A., Gillies, S. D., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200934 · Cited by 73
Self-citationSchumacher‐Kuckelkorn, R., Volland, R., Gradehandt, A., Hero, B., Simon, T., & Berthold, F. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26184 · Cited by 73
Genetic susceptibility to neuroblastoma: current knowledge and future directions
Egolf, L. E., Randall, M. P., Bosse, K. R., & Diskin, S. J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2820-3 · Cited by 79
“HACE1 knockout mice were shown to form a variety of spontaneous tumors and in the same study HACE1 inhibited anchorage-independent growth in a neuroblastoma cell line, further supporting a possible tumor suppressive function in neuroblastoma (Zhang et al. 2007).”
BackgroundThanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101934 · Cited by 78
“blastoma when combined with standard treatment [35].”
Bayeva, N., Coll, E., & Piskareva, O. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030211 · Cited by 77
TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
Boes, M. L., & Meyer‐Wentrup, F. A. G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.027 · Cited by 75
Cheung, I. Y., Hsu, K. C., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6236 · Cited by 73
“18, GM-CSF at 250 g/m(2)/d seemed beneficial for patient outcome.(13) In our study, at an even higher dose (500 g/m(2)/d for 3 days; Table 1), there was further granulocyte activation, which correlated with superior PFS.”
BackgroundMethodInfluentialGanglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma
Poon, V. I., Roth, M., Piperdi, S., Geller, D., Gill, J., Rudzinski, E. R., Hawkins, D. S., & Gorlick, R. (2015) · Clinical Sarcoma Research · doi:10.1186/s13569-014-0020-9 · Cited by 69
Carlson, L.-M., Rasmuson, A., Idborg, H., Segerström, L., Jakobsson, P., Sveinbjørnsson, B., & Kogner, P. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt009 · Cited by 76
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO
Siebert, N., Zumpe, M., Jüttner, M., Troschke‐Meurer, S., & Lode, H. N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1343775 · Cited by 76
Voeller, J., Erbe, A. K., Slowinski, J., Rasmussen, K., Carlson, P. M., Hoefges, A., VandenHeuvel, S. N., Stuckwisch, A. M., Wang, X., Gillies, S. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0823-6 · Cited by 79
Self-citationPaggio, J. C. D., & Tannock, I. F. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30338-9 · Cited by 80
Bona, K. O., Li, Y., Winestone, L. E., Getz, K., Huang, Y.-S. V., Fisher, B. T., Desai, A. V., Richardson, T., Hall, M., Naranjo, A. H., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa107 · Cited by 73
“Children randomly assigned to immunotherapy experienced statistically significantly improved EFS and randomization was stopped early (19), with all patients enrolled after 2009 assigned to immunotherapy.”
BackgroundMethodResultInfluentialHaploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma
Illhardt, T., Toporski, J., Feuchtinger, T. F., Turkiewicz, D., Teltschik, H., Ebinger, M., Schwarze, C.-P., Holzer, U., Lode, H. N., Albert, M. H., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.805 · Cited by 75
MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies
Agrawal, A., Rangarajan, V., Shah, S. A., Puranik, A. D., & Purandare, N. C. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180103 · Cited by 71
Lazarus, H. M., Ragsdale, C. E., Gale, R. P., & Lyman, G. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.706186 · Cited by 80
“Yu and colleagues and Cheung and colleagues reported improved progression-free survival (PFS) and survival in subjects receiving sargramostim-containing regimens compared to standard chemotherapy and historical controls, respectively (114, 116).”
Tian, M., Cheuk, A., Wei, J. S., Abdelmaksoud, A. A., Chou, H.-C., Milewski, D., Kelly, M. C., Song, Y., Dower, C. M., Li, N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155621 · Cited by 73
“Despite the recent improvements in outcomes with anti-GD2 immunotherapy, overall survival remains low at approximately 50% (4).”
Gargett, T., Truong, N. T., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., Yeo, E. C. F., Wittwer, N. L., Rico, G. T., Logan, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008659 · Cited by 75
Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma
Masetti, R., Biagi, C., Zama, D., Vendemini, F., Martoni, A., Morello, W., Gasperini, P., & Pession, A. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0047-3 · Cited by 79
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Kroesen, M., Büll, C., Gielen, P. R., Brok, I. C., Armandari, I., Wassink, M., Looman, M. W. G., Boon, L., den Brok, M. H., Hoogerbrugge, P. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1164919 · Cited by 71
“Vorinostat plus anti-GD2 mAb combination therapy in the absence of systemic cytokine administration.(3,14)”
BackgroundMarron, J. M., DuBois, S. G., Bender, J. G., Kim, A., Crompton, B. D., Meyer, S. C., Janeway, K. A., & Mack, J. W. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26137 · Cited by 73
Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Frühwald, M. C., Henze, G., Klingebiel, T. E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.011 · Cited by 74
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Bartolucci, D., Montemurro, L., Raieli, S., Lampis, S., Pession, A., Hrelia, P., & Tonelli, R. (2022) · Cancers · doi:10.3390/cancers14184421 · Cited by 74
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.